Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label chemotherapy plus craniospinal irradiation study in metastatic medulloblastoma and other embryonal tumors
2017-000801-19Phase 2Active
- Sponsor
- Meyer Organics
- Start
- Dec 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, etoposide, cyclophosphamide, carboplatin, thiotepa and 2 more in medulloblastoma, embryonal tumor, supratentorial embryonal tumor and 1 more, sponsored by Meyer Organics. Primary endpoints: Neurological toxicity, Serious adverse events and 2 more. Started Dec 2020; status: active.
02
Drugs
methotrexateetoposidecyclophosphamidecarboplatinthiotepa
03
Conditions
medulloblastomaembryonal tumorsupratentorial embryonal tumorpineoblastoma (PB)
Beyond the preview
Go deeper on 2017-000801-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000801-19.